United Kingdom Mammography Market Size

UK Mammography Market Analysis

The United Kingdom Mammography Market size is estimated at USD 83.72 million in 2024, and is expected to reach USD 127.28 million by 2029, growing at a CAGR of 8.74% during the forecast period (2024-2029).

The COVID pandemic had an adverse effect on the mammography market growth in the country. For instance, according to data from Breast Cancer Now, around 1 million British women missed their National Health Service breast screening in September 2020 as a result of the COVID-19 restriction. The UK's healthcare system is expected to be burdened by this procedural gap until 2022. Additionally, screening programs that aid in the annual diagnosis of 19,000 breast cancer cases in England were put on hold owing to COVID-19, causing a delay of more than 4 months. Likewise, in March 2020, similar initiatives were formally abolished in Scotland, Wales, and Northern Ireland. When compared to the preceding months of April and May 2019, Wales saw a decrease in the overall number of patients beginning breast screening treatment. However, beginning in 2021, screening practices are picking up steam in the United Kingdom, patients are increasingly being sent to cancer specialists, and breast cancer programs are now returning to their pre-pandemic levels. The United Kingdom's Gibraltar Health Authority (GHA) resumed its breast cancer screening program in March 2021 after ramping up to capacity during the epidemic. All patients who missed appointments during COVID-19 are being offered rescheduled appointments. Thus, the market is expected to grow in the future.

The UK mammography market is growing on account of the upsurge in the incidences of breast cancer, coupled with technological advancements in the field of breast imaging within the country. According to information provided by the Breast Cancer Now Organization, the nation will see an annual breast cancer diagnosis rate of around 55,000 women and 370 men in 2021. Furthermore, according to the same source, Scotland sees roughly 4,700 new cases of breast cancer each year. In a similar vein, each year there are around 2,800, 46,000, and 1,500 new cases of breast cancer in Wales, England, and Northern Ireland, respectively. Additionally, the early stage of breast cancer known as ductal carcinoma in situ (DCIS) affects about 7,000 people annually in the United Kingdom. On an account of these incidences, the demand for early diagnosis of diseases through the use of mammography is set to increase in near future.

Additionally, the National Health Service (NHS) Breast Screening Program was still successful in England in November 2020 in lowering the mortality rate from breast cancer. The Continuing Professional Development programme for Radiography and Mammography was introduced by the firm Fujifilm in the UK in October 2020. The goal of Cancer Research UK's partnership with Avon Foundation for Women, which is a component of Avon's Breast Cancer Promise, is to provide crucial breast cancer information to 100 million women annually. All of these national projects generate a massive amount of screening processes that increase the use, maintenance, and acquisition of advanced systems across the nation. Thus, the abovementioned factors are expected to increase the market growth.

However, the risk of adverse effects from radiation exposure, and reduction in reimbursement are expected to hinder the market growth.